Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Molecular Cancer Therapeutics|2025Cited by 20
Abstract B039: APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumorsAntoine Simoneau, Teng Teng, Steven Lombardo et al.|Molecular Cancer Therapeutics|2025Cited by 2
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Teng Teng, Matthew R. Tonini et al.|Biochimica et Biophysica Acta (BBA) - Molecular Cell Research|2025Cited by 1
Supplementary Figure S3 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Unknown|2025Cited by 0
Supplementary Table S4 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination DeficiencyAntoine Simoneau, Scott Throner, Charlotte B. Pratt et al.|Unknown|2025Cited by 0